Natera (NASDAQ:NTRA) Stock: Insider Solomon Moshkevich Sells 1,162 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,162 shares of the company’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total transaction of $495,407.08. Following the transaction, the insider owned 104,742 shares of the company’s stock, valued at approximately $44,655,704.28. The trade was a 1.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $414.30 on Friday. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41. The company has a 50-day moving average price of $377.06 and a 200 day moving average price of $266.44.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the company earned ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NTRA. Canaccord Genuity Group upped their price objective on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Guggenheim increased their price objective on Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. BTIG Research raised their target price on Natera from $320.00 to $430.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird set a $348.00 target price on shares of Natera in a research report on Friday, August 7th. Finally, Roth Capital assumed coverage on shares of Natera in a research note on Thursday, October 22nd. They set a “buy” rating and a $475.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $394.31.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in NTRA. BlackRock Inc. acquired a new stake in shares of Natera in the 2nd quarter worth approximately $2,962,770,000. Bank of America Corp DE purchased a new position in Natera in the 2nd quarter valued at approximately $199,960,000. Legal & General Group Plc acquired a new position in Natera during the second quarter worth $150,143,000. Bank of New York Mellon Corp acquired a new position in Natera during the second quarter worth $149,278,000. Finally, Avala Global LP purchased a new stake in Natera during the second quarter worth $124,867,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.